Life Science Investing Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Life Science Investing Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Life Science Investing Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 for the Treatment of PH-HFpEF
Life Science Investing Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Life Science Investing Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Life Science Investing Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Life Science Investing Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
CORRECTION: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and Announces $321,917 CEO Investment
Goldgroup Secures Ownership of the San Francisco Gold Mine Acquiring 100% of Molimentales del Noroeste, S.A. De C.V.
